Cardioprotection on Chemotherapy-Induced Cardiotoxicity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ACE Inhibitors, β -Blockers.
- Who it may be relevant to
- Registry conditions: Cardiotoxicity. Basic parameters: 1 year — 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Effect of Cardioprotective Medications on Chemotherapy-Induced Cardiotoxicity in Childhood Acute Leukemia
Overview
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
Detailed description
The goal of this interventional study is to evaluate the protective impact of Angiotensin-converting enzyme (ACE) inhibitors versus β-blockers on the cardiotoxicity profile of pediatric patients with acute leukemia. The impact is measured by evaluation of left ventricular ejection fraction (LVEF) by 2D echocardiography at baseline and at the end of Induction phase (42 days).
Interventions
- Drug ACE Inhibitors
0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse. - Drug β -Blockers
0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
Primary outcome measures
- Change in Left Ventricular Ejection Fraction (LVEF) [Time frame: LVEF will be measured at Baseline and at the end of Induction Phase (42 Days)]
Eligibility criteria
Inclusion criteria
- Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
- Ability to take oral medication.
- Age 2-18 years at the time of diagnosis.
Exclusion criteria
- Documented allergy to cardioprotective medications
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Egypt · 2 centers
- Faculty of Pharmacy, Ain Shams University — Cairo
- Faculty of Pharmacy, Ain Shams University — Cairo
Identifiers
NCT: NCT06853951 · 315